ReviewEuropean archives of psychiatry and clinical neuroscience2026
The role of tight junction proteins in the pathogenesis of schizophrenia.
Review in European archives of psychiatry and clinical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The blood-brain barrier (BBB) integrity is important for central nervous system homeostasis, and dysfunction of its components may contribute to the pathogenesis of various neuropsychiatric disorders, including schizophrenia. An additional factor supporting this hypothesis is the association of schizophrenia with DiGeorge syndrome, in which a deletion of a part of one copy of chromosome 22 (22q11DS) leads to haplonephrenia in the Claudin-5 gene (a tight junction protein that forms the BBB). Individuals with 22q11DS have a 25-fold greater risk of schizophrenia than the population average. The aim of our review was to establish the role of tight junction proteins in the pathogenesis of schizophrenia. For this purpose, a systematic literature search was performed. The first part describes genetic polymorphisms of tight junction proteins and studies of patients with DiGeorge syndrome. The second and third parts of the review focus on the expression of tight junction proteins in postmortem samples and serum. The fourth part of the review describes in vitro studies. The fifth part includes animal studies. Mice models with incomplete absence of the Claudin-5 gene have shown specific behavioral and memory impairments. The final part describes the effects of antipsychotics on tight junction proteins and BBB function. The discussed studies support the role of tight junction proteins in the pathogenesis of schizophrenia and the increased permeability of the BBB. However, the number of studies on this topic is extremely small. This review shows the prospects of studying tight junction proteins in psychiatric diseases.
Indexed as
Identifiers
41014348What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.